---
title: "Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295329030.md"
description: "Goldman Sachs maintained a Buy rating on Genmab A/S with a $33.50 price target in an August 7 report. While UBS also issued a Buy rating, Morgan Stanley kept a Hold rating for the company."
datetime: "2026-08-09T14:45:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295329030.md)
  - [en](https://longbridge.com/en/news/295329030.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295329030.md)
generator: "portal-rs"
---

# Goldman Sachs Sticks to Its Buy Rating for Genmab A/S (0MGB)

In a report released on August 7, Rajan Sharma from Goldman Sachs maintained a Buy rating on Genmab A/S, with a price target of $33.50. The company’s shares closed last Friday at DKK1,999.00.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and Immatics. According to TipRanks, Sharma has an average return of 2.6% and a 51.75% success rate on recommended stocks. 

In addition to Goldman Sachs, Genmab A/S also received a Buy from UBS’s Xian Deng in a report issued on August 7. However, on the same day, Morgan Stanley maintained a Hold rating on Genmab A/S (LSE: 0MGB).

### Related Stocks

- [GMAB.US](https://longbridge.com/en/quote/GMAB.US.md)
- [GS.US](https://longbridge.com/en/quote/GS.US.md)
- [AZN.US](https://longbridge.com/en/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/en/quote/AZN.UK.md)
- [GSK.US](https://longbridge.com/en/quote/GSK.US.md)
- [GSK.UK](https://longbridge.com/en/quote/GSK.UK.md)
- [IMTX.US](https://longbridge.com/en/quote/IMTX.US.md)
- [UBS.US](https://longbridge.com/en/quote/UBS.US.md)
- [MS.US](https://longbridge.com/en/quote/MS.US.md)
- [W4VR.SG](https://longbridge.com/en/quote/W4VR.SG.md)
- [GSK.WI.US](https://longbridge.com/en/quote/GSK.WI.US.md)
- [IMTXW.US](https://longbridge.com/en/quote/IMTXW.US.md)
- [MS-O.US](https://longbridge.com/en/quote/MS-O.US.md)
- [MS-Q.US](https://longbridge.com/en/quote/MS-Q.US.md)
- [MS-E.US](https://longbridge.com/en/quote/MS-E.US.md)
- [MS-I.US](https://longbridge.com/en/quote/MS-I.US.md)
- [MS-L.US](https://longbridge.com/en/quote/MS-L.US.md)
- [MS-P.US](https://longbridge.com/en/quote/MS-P.US.md)
- [MS-A.US](https://longbridge.com/en/quote/MS-A.US.md)
- [MS-F.US](https://longbridge.com/en/quote/MS-F.US.md)
- [MS-K.US](https://longbridge.com/en/quote/MS-K.US.md)

## Related News & Research

- [Genmab Eyes Three Pivotal Phase III Cancer Readouts in Q4](https://longbridge.com/en/news/300208333.md)
- [Genmab A/S (0MGB) Receives a Buy from Goldman Sachs](https://longbridge.com/en/news/285822044.md)
- [Gold extends the recovery amid renewed US-Iran deal hopes and dovish Fed's Williams comments](https://longbridge.com/en/news/300539305.md)
- [Buy the Selloff or Stay Away? Goldman Sachs Weighs In on FICO Stock](https://longbridge.com/en/news/300472842.md)
- [Polymarket Odds: Will MU, FDS Beat Earnings Tomorrow?](https://longbridge.com/en/news/300470494.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**